Abstract: The present invention relates to growth inhibition of microorganisms by lactic acid bacteria. The present invention also relates to the reduction and/or treatment of food-borne pathogen infections and/or nosocomial infections. The present invention also relates to the inhibition of spoilage microorganisms in food products. The present invention further relates to the modulation of gut flora. The invention is also directed to the inhibitory potential of a whey obtained from lactic acid bacteria.

Abstract: The invention relates to the use of Lactobacillus casei in orally administrable compositions for increasing protection against influenza after the influenza vaccine, by potentiating the humoral response generated by said vaccine.

Abstract: The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans, in combination with a cholesterol-reducing agent for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions.

Abstract: The present invention provides a strain of Lactobacillus fermentum SG-A95 with deposit number of CGMCC NO. 3248 and a fermentation product thereof. The present invention also provides a health care composition for improving oral bacteria population, which comprises the Lactobacillus fermentum SG-A95 or the fermentation product thereof.

Abstract: Dairy compositions are provided having a high pH, of about 4.8 to about 6.2, comprising desirable probiotic cultures as well as an anti-microbial system for inhibiting undesirable pathogenic and/or spoilage microbial growth without significantly reducing the beneficial effect of the probiotic cultures.

Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.

Abstract: Described are microorganisms which are, in a first aspect, able to stimulate the growth of microorganisms of the resident skin microbial flora and which do not stimulate the growth of microorganisms of the transient pathogenic micro flora. In a second aspect microorganisms are described which are able to inhibit the growth of microorganisms of the transient pathogenic skin micro flora and which do not inhibit the growth of microorganisms of the resident skin micro flora. Also described are compositions comprising such microorganisms as well as the use of such microorganisms in cosmetic, prophylactic or therapeutic applications.

Abstract: The present invention is directed to a novel method for increasing the production of acetate, decreasing the production of butyrate, increasing the population and species of beneficial bacteria and slowing the rate of fermentation of prebiotics within the gut of a formula-fed infant. The method comprises administration of a therapeutically effective amount of PDX to the infant.

Abstract: A nutritional composition is proposed comprising a probiotic and milk fat globule membrane (MFGM) wherein the MFGM and the probiotics mutually potentiate their respective effects and promote complementary beneficial protective mechanisms that reflect physiological synergy. The nutritional composition can be an infant formula, infant cereals, baby food or health care nutritional product. The synergistic effect can include promoting immune maturation and/or immune education and/or reducing inflammation and/or treating or preventing disease or infections.

Abstract: The invention provides a method and composition for ameliorating or reducing the symptoms, signs, and markers and for the treatment of irritable bowel syndrome, inflammatory bowel disease or gastritis in a mammal in need thereof, said method comprising administering effective amounts of a pharmaceutically acceptable composition containing at least one probiotic microorganism strain comprising Pediococcus for a time sufficient to ameliorate, reduce or treat at least one symptom, sign, or marker of irritable bowel syndrome, inflammatory bowel disease or gastritis.

Abstract: The invention provides a naturally occurring strain of Lactobacillus crispatus with advantageous characteristics. The strain colonizes mucosal surfaces, particularly vaginal surfaces. The strain is also capable of rapid growth in a number of conditions and is highly viable after desiccation. Moreover, the strain is capable of preventing and reducing pathogenic infection of vaginal mucosa.

Abstract: Various types of lactic acid bacteria were cultured in the presence of a purine, the amount of the purine consumed and the amount of purine degradation products produced were measured, and several lactic acid bacteria showing remarkable purine-decomposing ability were selected. Lactic acid bacteria that were assessed to have high purine-decomposing ability according to the above-mentioned selection were orally administered to rats reared on purine-containing feed, the general status and serum uric acid level of the rats were measured, and the effect of lactic acid bacteria administration on serum uric acid levels was examined. As a result, lactic acid bacteria that significantly suppress the increase of serum uric acid levels, Lactobacillus gasseri OLL2959 and Lactobacillus oris OLL2779, were found.

Abstract: The invention provides a composition for use in therapy of lactose intolerance or conditions arising from lactase deficiency, wherein the composition is a non-dairy solid dosage form comprising: (a) a lactase; and (b) one or more lactase-producing and/or lactase containing microorganisms selected from Lactobacillus delbrueckii ssp bulgaricus and Steptococcus thermophilus; wherein the lactase (a) is other than a lactase derived from the said one or more microorganisms (b); and wherein the one or more lactase-producing and/or lactase-containing microorganisms (b) are in dried form. Also provided are uncoated capsule and tablet compositions containing the lactase and the lactase-producing and/or lactase-containing microorganisms.

Abstract: The invention relates to novel strains of Lactobacillus helveticus. More specifically, the invention relates to strains of Lactobacillus helveticus having a lactose-negative phenotype and to the uses thereof in the agri-food industry. The invention also relates to a method for obtaining such strains of Lactobacillus helveticus.

Abstract: The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of Lactobacillus as well as the use of said non-fermented composition as a synbiotic and for treatment of the metabolic syndrome, ulcerative colitis, Crohns disease, Irritable bowel syndrome (IBS), or Inflammatory bowel disease (IBD). The non-fermented composition of the invention is useful for the maintenance of a healthy gut-mucosa and/or for the provision of an increased barrier function of the gutmucosa.

Abstract: The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impaired radiance of the skin's complexion.

Abstract: An exemplary embodiment providing one or more improvements includes probiotic compositions comprising probiotic microorganisms with dried vegetable, fruit, cereal, or herb powder. Feeding human or animals either having biological or environmental changes with probiotic compositions has a positive effect in relieving the changes. Positive effects has been demonstrated in humans, dogs, and fish.

Abstract: The present invention generally relates to the field of weight management and obesity. In particular the present invention relates to the use of probiotics in combination with prebiotics to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus NCC 4007 in combination with a specific probiotic mixture for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

Abstract: The present invention generally relates to the field of obesity. In particular the present invention relates to the use of probiotics to support weight management and to treat or prevent obesity. One embodiment of the present invention relates to the use of Lactobacillus rhamnosus CNCM I-4096 for the preparation of a composition to support weight management, promote weight loss and/or to treat obesity.

Abstract: Prosthetic apparatuses with probiotic microorganisms to control colonization of pathogenic bacteria are disclosed. The prosthetic apparatus may include a first portion having a first mating surface, a second portion having a second mating surface that conforms to the first mating surface, and at least one strain of probiotic microorganisms retained between the first and second mating surfaces prior to implantation of the prosthetic apparatus.

Abstract: The invention provides compositions and methods for utilizing synthetic human milk oligosaccharides as prebiotics.

Abstract: The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impairments of the skin's microrelief.

Abstract: A liquid encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liquid plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liquid plasticizer and the encapsulation of the active encapsulant is accomplished at a low temperature and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liquid content of the liquid encapsulant component provides substantially all or completely all of the liquid plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixture or dough. Removal of liquid plasticizer prior to extrusion is not needed to adjust the viscosity of the mixture for formability.

Abstract: The disclosure relates to a solid glass matrix of polysaccharides, monossaccharides or disaccharides in combination with polyols as delivery vehicles for preservation and post gastric administration of a probiotic. The delivery vehicle is capable of releasing the probiotic at their site of action. The present invention further includes methods of making and using the solid glass matrix delivery vehicle of the invention.

Abstract: One aspect of the present invention relates to an edible product containing: • probiotic bacteria in an amount of at least 103 bacteria per gram; and • at least 0.5 mg/g of ginseng polysaccharides containing at least 2 monosaccharide units, preferably at least 4 monosaccharide units. Another aspect of the invention relates to the use of the aforementioned product in therapeutic and prophylactic treatments. The present invention further provides a method of producing a packaged liquid edible product containing probiotic bacteria and ginseng polysaccharides in the aforementioned amounts.

Abstract: The invention relates to a probiotic combination comprising different combinations of lactobacilli, propionic acid bacteria and/or bifidobacteria. The probiotics are preferably combined with a suitable prebiotic to form a synbiotic. The combination of the invention can be consumed as such or combined with a suitable foodstuff or pharmaceutical product, and it is therapeutically useful for example for stimulating the immune system and for general health improvement.

Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.

Abstract: The present invention relates to the field of probiotics. More particularly, the invention pertains to the use of a particular strain, Lactobacillus casei CNCM I-1518, which is present in Actimel®, for alleviating the symptoms of a delayed-type hypersensitivity reaction.

Abstract: The method of the present invention comprises the administration of a complete matrix of natural whole food vitamins, minerals including necessary electrolytes, super anti-oxidants, proteins, amino acids, complex carbohydrates, fiber, lipids and bio-flavonoids with superior absorption, utilization and retention. The supplement provides a consumer or athlete enhanced hydration retention and energy which is extremely effective in enhancing exercise and sports performance.

Abstract: The present invention relates to multi-coated lactic acid bacteria coated with a multi-coating layer forming bacterial clusters and including protein, polysaccharide, and edible oil/fat component, and a preparing method thereof. The multi-coated lactic acid bacteria according to the present invention may achieve an improved acid resistance, a bile resistance, and an accelerated test stability, may have a low moisture content to be particularly stable against a moisture variation, and thus may be appropriately used to prepare various products including lactic acid bacteria.

Abstract: Disclosed are quick dissolve tablets, each including freeze dried lysate of Lactobacillus reuteri, Lactobacillus casei, Lactobacillus plantarum, Llactobacillus rhamnosus GG, Lactobacillus acidophilus, Bifidobacterium bifidium, Bifidobacterium longum, Bifidobacterium infantis or Bifidobacterium breve and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a sufficient dosage for therapeutic effect, one such formulation being: four parts of bacterial lysate and one part of N-acetyl D-glucosamine. Excipients can include one or more of, maltodextrin; xanthan gum; acesulfam K; lemon powder and a flavoring, e.g., juice; Mannitol TL-32-04, Microcrystalline Cellulose and Carrageenan, Fructose, PVP-XL TL-11-04, Gellan Gum, Citrus TL 1-04, Orange TL 19-04, Sucrolose TL-13-04, and Mg ST TL-13-04.

Abstract: Methods and compositions for treating inflammatory bowel disease involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic. The practice of the invention may reduce or eliminate the use of immunosuppressants in the treatment and management of IBD.

Abstract: The invention relates to a composition for improving the syndrome of diabetes and complication thereof. The composition comprises an effective amount of Lactobacillus strain which is at least one selected from the group consisting of: Lactobacillus reuteri GMNL-89 strain, Lactobacillus gasseri GMNL-205 strain, Lactobacillus reuteri GMNL-263 strain and a pharmaceutical acceptable vehicle. The Lactobacillus gasseri GMNL-205 strain and Lactobacillus reuteri GMNL-263 strain are novel isolated Lactobacillus strains. In addition, the invention also relates to a novel use of the composition or the Lactobacillus strains for improving the syndrome of diabetes and complication thereof.

Abstract: The invention covers a novel treatment strategy that considerably improves conventional probiotic treatments of inflammatory bowel diseases, irritable bowel syndrome and other gastrointestinal disorders. Both probiotic microorganisms and the carrier of the probiotic microorganisms in form of a fermented cereal gruel are used as treatment effectors. Phospholipids may also be an effecter. The novel treatment strategy is capable of removing the symptoms of inflammatory bowel diseases regardless of a mild, moderate or severe stage of the disease.

Abstract: The present invention relates to the field of nutrition for infants and young children. In particular, the present invention relates to growing-up milks comprising probiotic micro-organisms to be administered to infants and young children older than 10 months. These probiotic micro-organisms may be non-replicating probiotic micro-organisms such as bioactive heat treated probiotic micro-organisms, for example.

Abstract: The present invention claims the use of pomegranate (Punica granaturn) plant extracts and various combinations of said extracts, some additionally including a probiotic, which allow a synergistic effect between the bioactive components thereof, for the purpose of preparing dietary supplements, functional foods/beverages, food additives and drugs for use in caring for human health.

Abstract: The present invention relates generally to enhanced activity of certain probiotics. The increased efficacy is achieved by using certain substrate components that indirectly supply the probiotics with a specific source of energy. The substrate components are specifically designed to stimulate 1,2-propanediol production.

Abstract: The invention relates to a pharmaceutical and/or dietetic composition for increasing the impact of the immune defense of higher living beings, wherein bacteria of the species Lactobacillus fermentum from at least one of the strains K1-Lb1 or K1-Lb6 or K2-Lb4 or K6-Lb4 or K7-Lb1 or K8-Lb1 or K9-Lb6 are contained in order to control the adaptive and natural immune defense by means of T helper 1 and T helper 2 cells and/or bacteria of the species Lactobacillus fermentum from at least one of the strains K2-Lb6 or K11-Lb3 are contained in order to strengthen the native immune defense.

Abstract: The present invention relates to the use of benzoic acid and/or its sodium salt in combination with saccharide(s) as active components in the manufacture of a vaginal composition for modulating vaginal flora and vaginal acidity, thereby maintaining the pH value of vaginal secretion within a range from 3.5 to 4.5; and the present invention further relates to a vaginal composition and a method for modulating and maintaining normal vaginal flora and vaginal acidity.

Abstract: The kit comprises applicators of lubricating composition for use during the days up to and including ovulation and applicators of a slightly thicker composition for use just after ovulation. The lubricating composition is neutral or slightly acid with a view to being sperm friendly. The thicker composition is slightly acid to mirror vaginal acidity and includes a moisturiser for vaginal friendliness. It is also a lubricant.

Abstract: The isoflavone equol has the ability to mimic estrogen at the receptor level, as well as the ability to mitigate the deleterious effects of dihydrotestosterone (DHT) in vivo, thus resulting in potential health benefits for both men and women. Only an approximated one-third of the global population has the inherent ability to produce equol. Diet and colonic bacterial composition play a large role in natural equol production. The present invention can increase the probability of producing significant quantities of equol in vivo. Experimentation has shown the repeatable and measurable evidence of equol. Data from male test subjects indicates clinically significant positive effects on androgenic alopecia and acne vulgaris.

Abstract: A probiotic composition including a probiotic microorganism embedded within a matrix, the matrix substantially maintaining the viability of said microorganisms. The matrix releases said microorganisms into and upon contact with a liquid carrier. The invention includes methods for manufacturing the composition, particular forms of the composition (2) and as apparatus for administration.

Abstract: Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a sufficient dosage for therapeutic effect, one such formulation being: 50 mg of Lactobacillus delbrueckii subsp bulgaricus lysate strain YB-I 10 mg of N-acetyl D-glucosamine. Excipients can include one or more of, maltodextrin; xanthan gum; acesulfam K; lemon powder and a flavoring, e.g., juice; Mannitol TL-32-04, Microcrystalline Cellulose and Carrageenan, Fructose, PVP-XL TL-11-04, Gellan Gum, Citrus TL 1-04, Orange TL 19-04, Sucrolose TL-13-04, and Mg ST TL-13-04.

Abstract: A suppository is provided for rectal, vaginal or urethral administration. A method also is provided for the preparation of a suppository for rectal, vaginal or urethral administration. The method uses at least one unsaturated, non-esterified fatty acid in a composition containing a probiotic and an antibiotic.

Abstract: The present invention relates to a microorganism belonging to the group of lactic acid bacteria capable of specifically binding to Streptococcus mutans, wherein the specific binding is (i) resistant to heat treatment; (ii) resistant to protease treatment; (iii) calcium-dependent; (iv) formed within a pH range between 4.5 and 8.5; and/or (v) formed in the presence of saliva. The present invention is also relates to an analog or fragment of the microorganism which is thermally inactivated or lyophilized, wherein the analog or fragment retains the capability of specifically binding to Streptococcus mutans. The invention further encompasses compositions and additives for food, feed or drinks comprising the microorganism or an analog or fragment thereof. Also provided is uses of the microorganism or an analog or fragment thereof for the preparation of an anticariogenic or pharmaceutical composition or anticariogenic food or feedstuff as well as methods for producing the compositions or food or feedstuff.

Abstract: The invention relates to the field of health-promoting compositions and to their preparation method.

Abstract: The present invention relates to compositions, including live organisms, nucleic acid and amino acid sequences, constructs and cells comprising these, which are used to competitively exclude pathogenic organisms from the alimentary canals of vertebrates to achieve prophylaxis or therapeutic effects.

Abstract: Use of at least one strain of a microorganism and/or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and/or a metabolite thereof may be administered to the subject for the treatment and/or prevention of excess weight and/or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and/or a metabolite thereof is administered to the subject for the treatment and/or prevention of obesity and/or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and/or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and/or B. lactis.

Abstract: A nutritional composition for reducing oxidative damage and lipid peroxidation in humans, while allowing for the oxidative reactions necessary to sustain vital biological functions. The nutritional compositions comprise adaptogens comprising astragalus root, ashwagandha root, cordyceps, holy basil leaf, maca root, reishi mushrooms, schisandra, and suma root; superfoods comprising acerola, camu-camu, pomegranate, bilberry, blueberry, Goji berries, Acai, maitake, citrus bioflavonoids, rose hips, and Gingko biloba; probiotics comprising Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus acidophilus DDS-1, Lactobacillus bulgaricus, Lactobacillus casei, and Streptococcus thermophilus; and enzymes comprising amylase, papain, cellulase, lactase, lipase, protease, and bromelain. The nutritional compositions may also be provided as a meal replacement and further comprise one or more plant products, algae, vitamins, minerals, protein and methylsulfonylmethane (MSM).

Abstract: The present invention provides a composition comprising prebiotic and probiotic components and is used to reduce elevated levels of nitrogenous waste products and to promote a healthy bowel microenvironment.